Haploidentical CD3 TCRαβ and CD19-depleted second stem cell transplant for steroid-resistant acute skin graft versus host disease

Abstract

This study was funded by university departmental funds. Disclosure of potential conflict of interest: A. Manoharan has received travel support from Chiesi. B. Lipworth has received research support and consultancy fees from Chiesi, Teva, and Meda; has received travel support from Chiesi; is on the Boehringer Ingelheim advisory board; has received consultancy fees from Boehringer Ingelheim; has received research support from Janssen, AstraZeneca, Roche, and Pearl; and has mutual fund investments containing most of the large international pharmaceutical companies. The rest of the authors declare that they have no relevant conflicts of interest.

T-cell receptor αβ+ and CD19+ cell–depleted haploidentical and mismatched hematopoietic stem cell transplantation in primary immune deficiency

“…Patient 5 with disseminated BCG before transplantation and patient 20 with disseminated enterovirus infection after transplantation had immune reconstitution inflammatory syndrome. 20 TMA developed in patients 7 and 26, who responded to supportive measures with defibrotide 19 in 1 and eculizumab 22 in another. Three patients had features of posterior reversible encephalopathy syndrome, which responded to discontinuation of cyclosporine.…”

Haploidentical transplantation in pediatric non‐malignant diseases: A retrospective analysis on behalf of the Spanish Group for Hematopoietic Transplantation (GETH)

“…Although PT‐Cy data are scarce, 28,47,48 published data suggest that this treatment option could be an alternative for improving GvHD rates and increasing survival in patients with NMD who undergo haplo‐HSCT 48 . Outcomes with the TCR αβ + CD19 + depleted haplo‐HSCT approach in which no additional GvHD prophylaxis was employed appear promising in malignant disease and NMD 3,49,50 . Clinical results with CD45RA + TCD in the context of haplo‐HSCT are still limited 51 .…”

“…48 Outcomes with the TCR αβ + CD19 + depleted haplo-HSCT approach in which no additional GvHD prophylaxis was employed appear promising in malignant disease and NMD. 3,49,50 Clinical results with CD45RA + TCD in the context of haplo-HSCT are still limited. 51 Our PID results using CD45RA + TCD grafts are poor and insufficient for providing useful information.…”

Haploidentical transplantation in pediatric non-malignant diseases: A retrospective analysis on behalf of the Spanish Group for Hematopoietic Transplantation (GETH)

“…Although PT-Cy data are scarce 39,43,46 , published data suggest that this treatment option could be an alternative to improve GvHD rates and increase survival in NMD patients who receive haplo-HSCT 50 . Outcomes with the TCR αβ + CD19 + depleted haplo-HSCT approach in which no additional GvHD prophylaxis was employed appear promising in malignant and NMD 3,23,47 . Clinical results with CD45RA + TCD in the context of haplo-HSCT are so far limited 48 .…”